The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://abellflw422365.izrablog.com/39450919/glp-3-retatrutide-a-comparative-analysis